Hot Topic QuickTakes VL

PSA Versus Imaging Monitoring in mCRPC - Alan Bryce

Monitoring prostate-specific antigen (PSA) vs. imaging monitoring in metastatic castration-resistant prostate cancer (mCRPC) Biographies: E. David Crawford Alan Bryce, MD Related Content: Prognostic significance of time to prostate-specific antigen (PSA)

Leonard Gomella on Bone Metastases and Mortality: Can We Be Doing More?

Biography: Leonard Gomella, MD The Bernard W. Godwin, Jr. Professor of Prostate Cancer Chairman, Department of Urology Clinical Director, Jefferson Kimmel Cancer Center Network Senior Director for Clinical Affairs, Jefferson Kimmel Cancer Center

Bladder Cancer Biomarkers: Optimal utilization for diagnosis and recurrence pipeline- Badrinath Konety

E. David Crawford is joined by Badrinath Konety, MD for a video lecture on novel bladder cancer markers and currently available bladder cancer markers and how they can possibly be applied to the practice of urology and potential bladder cancer markers that are in the pipeline. Biography: Badrinath R. Konety, M.D., M.B.A., is Professor and Chair of the Department of Urology and holds the Dougherty...

Germline Mutations in Prostate Cancer - Salvatore Catarinicchia

Salvatore Pietro Catarinicchia M.D., Urology Resident Physician at the University of Colorado, discusses the latest evidence on "Germline mutations in ATM and BRCA1/2 genes could help predict death risk from aggressive prostate cancer" with E. David Crawford, MD. During their dialogue, Dr. Crawford shares a recent patient experience with Dr. Catarinicchia that demonstrates the clinical implication...

Origins of The U.S. Preventive Services Task Force- Deepak Kapoor

Dr. David Crawford invites Dr. Deepak Kapoor to provide a lecture on the origins and background of The U.S. Preventive Services Task Force (USPSTF). This presentation is especially timely and important with the USPSTF's recommendation against prostate-specific antigen (PSA)-based screening for prostate cancer. Biography: Deepak A. Kapoor, MD Chairman and Chief Executive Officer Integrated Medical...

Point- CounterPoint: Are Novel Biomarkers Ready For Primetime in Routine Detection of Prostate Cancer? -Badrinath Konety

Dr. David Crawford invites Dr. Badrinath Konety to provide a counterpoint discussion on novel biomarkers and their use in detecting prostate cancer. Although, Dr. Konety agrees with the value of biomarkers and that they can be used in addition to PSA tests, he is not sure they are ready for prime time. Dr. Konety proposes key questions on novel biomarkers including their level improvement, are the...

Point - CounterPoint: Are Novel Biomarkers Ready For Primetime in Routine Detection of Prostate Cancer?- Scott Eggener

Dr. David Crawford invites Dr. Scott Eggener to participate in a point-counter point discussion on novel biomarkers in the detection of prostate cancer. Dr. Eggener lectures includes information on different biomarkers and reviews the data that supports his position that novel biomarkers are ready for prime time. Novel prostate cancer screening biomarkers preserve benefits of screening and dramati...

MRI/US Fusion Prostate Biopsy - Mitchell Humphreys

E. David Crawford is joined by Dr. Mitchell R. Humphreys to discuss the role of MRI and fusion biopsies in detection of prostate cancer. One of the key advantages of this technology is being able to find high grades level of cancer, that may go undetected, resulting in the ability to better manage high risk prostate cancer leading to improvements for patients overall. Biography Mitchell R. Humphre...

5 Alpha Reductase Inhibitors & Chemoprevention of Prostate Cancer with Dr. Marc Garnick

E. David Crawford invites Dr. Marc Garnick to review the major findings and supportive studies for the proposed use of the 5-alpha-reductase inhibitors (5-ARIs), finasteride and dutasteride, for prostate cancer chemoprevention that was rejected by the FDA in 2010. The implications of the pivotall stuides for 5-ARI use as prostate cancer prevention are also discussed by Dr. Garnick. Biography: Dr....

Immunotherapy in Genitourinary Cancers: T-cell Activation and Check Point Therapies - Sumit Subudhi

Sumit Subudhi presents exciting data on immunotherapy and check point inhibitors in genitourinary cancer. Dr. Subudhi’s discussion includes data on patient overall survival in renal cell carcinoma and a case study showing a remarkable example of a patient being treated with ipilimumab and resulting in a durable and curative response. Biography Sumit K. Subudhi, MD, PhD Assistant Professor, Departm...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.